Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. The topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, nanosimilars, and nano-biosimilars. The journal is open for the publication of studies conducted at the basic science, clinical development, and clinical trial stages. Furthermore, publications that address safety, pharmacovigilance regulatory, and ethical issues are welcome. We invite you to consider submitting your work to Biomedicines, be it original research or review articles, or toward developing Special Issues of current key topics.
The aim of Biomedicines is to publish high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development and, ultimately, to clinical use. Therefore, basic research, comprehensive preclinical studies, clinical development, and clinical trials are all within the scope of the journal.
- Pathogenesis and mechanisms of diseases
- Translational medical research
- Biomaterial in biomedical research
- Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology
- Biomarker discovery and early diagnosis research
- Drug discovery and drug development, biomedicine, and pharmacotherapy
- Natural biomedicine, including marine, plant, and animal-derived biomedicine
- Biopharmaceutical biomedicine: biologics and biosimilars
- Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bio-imaging, gene therapy, vaccine, cell therapy, and tissue engineering
- Pharmacovigilance, regulatory, and ethical issues
MDPI Publication Ethics Statement
Biomedicines is a member of the Committee on Publication Ethics (COPE). MDPI takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, inappropriate authorship credit, and the like, do arise. MDPI takes such publishing ethics issues very seriously and our editors are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use iThenticate to check submissions against previous publications. MDPI works with Publons to provide reviewers with credit for their work.
Authors and publishers are encouraged to send review copies of their recent related books to the following address. Received books will be listed as Books Received within the journal's News & Announcements section.
Copyright / Open Access
Articles published in Biomedicines will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). The copyright is retained by the author(s). MDPI will insert the following note at the end of the published text:
Announcements regarding academic activities such as conferences are published for free in the News & Announcements section of the journal. Advertisement can be either published or placed on the pertinent website. Contact e-mail address is . For further MDPI contacts, see here.
Announcement and Advertisement
Announcements regarding academic activities such as conferences are published for free in the News & Announcements section of the journal. Advertisement can be either published or placed on the pertinent website. Contact e-mail address is .
For further MDPI contacts, see here.